Generic Name

Lisinopril

Brand Names
Qbrelis, Zestoretic, Zestril
FDA approval date: July 01, 2002
Classification: Angiotensin Converting Enzyme Inhibitor
Form: Tablet, Solution

What is Qbrelis (Lisinopril)?

QBRELIS is an angiotensin converting enzyme inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Summary: Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases. Although technical advances have reduced treatment-related illness and death, radiation exposure to the heart can still cause substantial rates of radiation-induced heart disease (RIHD) among survivors. For example, about 21% of non-small cell lun...

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

Summary: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whethe...

The Effect Of Lisinopril On Polycythemia

Summary: The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whet...

Brand Information